Abstract
More than 150, 000 patients undergo ablation for atrial fibrillation (AF) each year.Current guidelines recommend oral anticoagulation in all patients undergoing AF ablation. A large number of patients undergoing cardiac implantable electronic devices (CIEDs) are on long-term oral anticoagulation. These patients are at increased risk for thromboembolism with interruption of oral anticoagulation. Due to the increased risk for bleeding complications during the procedure combined with the need to prevent thromboembolism, periprocedural management of anticoagulation in these patients can be challenging. In this article we review the current evidence for periprocedural management of oral anticoagulation in patients undergoing ablation and CIED implantation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
